Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

Stock Information for Lineage Cell Therapeutics, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lineage Cell Therapeutics, Inc.

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026
Deborah D. Ascheim, M.D. Elected to Longeveron Board of Directors
Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer's Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer's Disease
Longeveron® Appoints Marie Washburn as Chief Financial Officer
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer's Disease Accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference (AAIC)
Longeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)
Longeveron to Present at BIO International Convention 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.